aTyr Pharma financials
$0.3077+3.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $190.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $190.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | 100.0% | — | — | — | — | — |
| Operating income | -$10.9M | -$11.4M | -$14.8M | -$26.7M | -$20.3M | -$15.8M | -$15.8M | -$18.1M | -$17.3M |
| Net income | -$10.3M | -$10.8M | -$14.0M | -$25.7M | -$19.5M | -$14.9M | -$15.0M | -$17.3M | -$16.3M |
| Net margin | — | — | — | −13549.5% | — | — | — | — | — |
| Diluted EPS | $-0.11 | $-0.11 | $-0.14 | $-0.26 | $-0.22 | $-0.17 | $-0.18 | $-0.23 | $-0.23 |
| EBITDA | -$10.7M | -$11.3M | -$14.6M | -$26.6M | -$20.1M | -$15.6M | -$15.6M | -$18.0M | -$17.1M |
| Operating cash flow | -$9.4M | -$12.5M | -$12.2M | -$20.5M | -$13.9M | -$15.4M | -$13.1M | -$13.2M | -$20.4M |
| Free cash flow | -$9.4M | -$12.7M | -$12.2M | -$20.5M | -$13.9M | -$15.4M | -$13.2M | -$13.2M | -$20.5M |
| Diluted shares | 98.1M | 98.0M | 98.2M | 97.2M | 90.1M | 86.5M | 82.9M | 75.8M | 72.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $16.2M | $10.0M | $10.7M | $6.2M | $17.2M | $10.4M |
| Short-term investments | $41.3M | $56.5M | $67.9M | $84.1M | $63.1M | $66.0M |
| Total debt | $554.0K | $747.0K | $889.0K | $1.0M | $1.2M | $1.3M |
| Total assets | $69.8M | $79.7M | $93.0M | $106.7M | $101.5M | $97.2M |
| Total liabilities | $21.2M | $21.9M | $25.7M | $26.6M | $26.9M | $22.4M |
| Shareholders' equity | $48.6M | $57.7M | $67.3M | $80.0M | $74.7M | $74.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology